How many clinical trials are studying AK112?

6 recruiting trials in our tracked data involve AK112.

What conditions is AK112 being studied for?

In our tracked recruiting trials, AK112 is being studied in trials for Lung cancer, Advanced Non-small Cell Lung Cancer (NSCLC), Breast cancer.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 1 1 Phase 2 3 Phase 3 3

Condition	Trials
Lung cancer · AK112 for Lung cancer	3
Advanced Non-small Cell Lung Cancer (NSCLC)	1
Breast cancer	1
Colorectal Adenocarcinoma	1
Colorectal cancer	1
Lung Cancer, Non-Small Cell	1
Pancreatic Cancer	1
Small Cell Lung Cancer	1
Triple-Negative Breast Cancer (TNBC)	1

A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
NCT06769295 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
NCT07114315 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
NCT06951503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
NCT06767527 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
AMT-116 in Combination With AK112 in Patients With Lung Cancer
NCT07590531 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations